Ambitious Danish biotech fund shuts down before first investment
Ambitions were high when Sund Capital, headed by the former Zealand Pharma CEO David Solomon, announced plans to raise up to DKK 2 billion (EUR 268 million) for investments in up-and-coming biotechs. But now the fund is closing down.

Mikkel Aabenhus Hemmingsen
With a total loss of DKK 2.9 million after 18 months, the end has come for Sund Capital which was founded in summer 2016 with the aim of investing up to DKK 2.2 billion in Nordic biotechs.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app